# A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19

> **NCT06147063** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 243 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** AZD9838
- **BIOLOGICAL:** Licensed mRNA vaccine
- **BIOLOGICAL:** AZD6563

## Key facts

- **NCT ID:** NCT06147063
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-27
- **Primary completion:** 2024-04-30
- **Final completion:** 2025-03-27
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06147063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06147063, "A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06147063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*